Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation

Blood. 2016 Sep 15;128(11):1528-31. doi: 10.1182/blood-2016-06-723205. Epub 2016 Aug 5.

Authors

Raffaella Greco¹, Francesca Lorentino¹, Mara Morelli¹, Fabio Giglio¹, Daniele Mannina¹, Andrea Assanelli¹, Sara Mastaglio¹, Serena Dalto¹, Tommaso Perini¹, Lorenzo Lazzari¹, Simona Piemontese¹, Consuelo Corti¹, Magda Marcatti¹, Massimo Bernardi¹, Maria Teresa Lupo Stanghellini¹, Fabio Ciceri², Jacopo Peccatori¹

Affiliations

¹ Hematology and Bone Marrow Transplantation Unit, and.
² Hematology and Bone Marrow Transplantation Unit, and University Vita-Salute San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.

PMID: 27495140
DOI: 10.1182/blood-2016-06-723205

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Chemoprevention / methods
Cyclophosphamide / administration & dosage*
Female
Graft vs Host Disease / prevention & control*
Hematologic Neoplasms / therapy
Histocompatibility Testing
Humans
Male
Middle Aged
Peripheral Blood Stem Cell Transplantation / adverse effects
Peripheral Blood Stem Cell Transplantation / methods*
Sirolimus / administration & dosage*
Transplantation Conditioning / methods*

Substances

Cyclophosphamide
Sirolimus